Study the effect of static magnetic field intensity on drug delivery by magnetic nanoparticles

Abbas Moghanizadeh1, Fakhereddin Ashrafizadeh2, Jaleh Varshosaz1,2 & Antoine Ferreira3

Employing the magnets in therapy has a long history of treating diseases, and currently new applications such as drug delivery by magnetic nanoparticles are gaining more attention. This research tried to study the effect of static magnetic field intensity on drug delivery by magnetic nanoparticles carrying thrombolytic agents. In this research, Fe3O4@SiO2 nanoparticles carrying streptokinase were applied. The efficiency of thrombolysis and micro-CT-scan images are utilized to study the effect of different magnetic fields (0.1, 0.2, 0.3 and 0.5 T) on thrombolysis. The results confirm that increasing the static magnetic field intensity accelerated the thrombolysis. Increasing the intensity of the magnetic field from 0.1 to 0.3 T leads to an increase in clot dissolution rate from 55 to 89%, respectively. Moreover, micro-CT-scan images revealed that magnetic nanoparticles carrying a thrombolytic agent penetrated deeper into the mesh-like structure of clot as the magnetic field intensities increased, which could lead to further dissolution of the clot.

Using the magnet therapy has been considered since ancient times1. Due to the change of magnetic field with time, the magnetic field is divided into two categories, static and dynamic magnetic fields2. While the dynamic magnetic field is classified by parameters such as frequency, the static magnetic field is classified according to the intensity of the magnetic field1. Although the magnetic field is used to treat a large number of diseases in a variety of ways, one of the significant applications of the magnetic field is in drug delivery by magnetic nanoparticles (MNPs)3. Not only does the magnetic field direct the magnetic nanoparticles carrying the drug to a specific point, but it also affects the release of the drug3. Although many studies have been performed on dynamic magnetic field parameters such as frequency4 or phenomena such as hyperthermia5 in the treatment of diseases such as cancer or thrombosis by magnetic nanoparticles, the effect of static magnetic field intensity on drug delivery by magnetic nanoparticles in thrombolysis has received less attention. Despite the widespread use of static magnetic fields in thrombolysis by magnetic nanoparticles carrying thrombolytic agents, scientific evidence for the effect of the intensity of a static magnetic field in thrombolysis would be valuable.

Thrombolysis is defined as the dissolving of abnormal blood clots to improve blood flow6. Recently, blood loss, embolization, or thrombus, has been known as the main reason for serious damages such as stroke disabilities or even death. Stroke threat the health of approximately 15 million people every year, while one-third of them suffering from permanent disabilities and five million deaths occurred worldwide7. Moreover, it escalates the costs of the health system, whereas it is estimated that the 2–5% of the total healthcare expenditure8. The first strategy for thrombolysis is the intravenous or intra-arterial injection of various types of thrombolytic agents. Despite the significant therapeutic outcomes, there are some drawbacks including non-specific thrombolytic substance to fibrin in some types of them, high cost, short half-life, and time window for initiating therapy have resulted in the development of new strategies for thrombolysis9. Drug delivery is a promising and efficient approach for thrombolysis to release the thrombolytic agents in a controlled manner. Various types of mesoporous10, core–shell11 and magnetic and nonmagnetic12 nanoparticles have been employed for controlled release of thrombolytic agents. Various types of core–shell nanoparticles have been developed to controlled release of thrombolytic agents such as tPA and Streptokinase13. Magnetic and nonmagnetic cores are frequently utilized to tackle blood clots. While magnetic nanoparticles have the potential to control and guide under magnetic fields, magnetic iron oxide (Fe3O4) nanoparticles regularly used as a core for thrombolysis due to its biocompatibility, as well as its unique multifunctional properties. In research, the potential of the magnetic core of Fe3O4 coated by silica (SiO2) for thrombolytic and for better conjugating with tPA was studied15. Tadayon also showed that a combination of

1Department of Materials Engineering, Isfahan University of Technology, Isfahan 84156-83111, Iran. 2Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. 3INSa Centre Val de Loire, Université d’Orléans, PRISME EA4229, Bourges, France. *email: Abbas.moghanizadeh@gmail.com
MNP@SiO₂-tPA-SK with static magnetic field could effectively shorten thrombolysis time (87%) compared with conventional treatment with free tPA. Moreover, applying a static magnetic field roughly 20% increases the efficiency of thrombolysis. In a study carrying thrombolytic agent (urokinase) by magnetic nanoparticles with a particle size of 116 nm and static magnetic field strength of 0.5 T, the clot dissolved is 55% more than the free drug. Also it is reported that carrying tPA with nanoparticles with a size of 119 nm and a magnetic field of 0.6 T, the dissolution of the clot has increased by 20% compared to the free drug. The use of a static magnetic field with a magnitude of 0.4 T has also led to a 10% increase in the efficiency of thrombolysis compared to the free drug.

According to researches, the effect of magnetic field on thrombolysis by magnetic nanoparticles carrying thrombolytic agents is undeniable, but so far, the mechanism of magnetic field on dissolving clots has not been studied in depth. According to our knowledge, thrombolysis by magnetic nanoparticles carrying thrombolytic agents under different static magnetic field strengths has not been investigated, yet. The aim of this research was to study the synergic effect of thrombolysis agents and magnetic field strengths on thrombolysis. Here, we studied the role of the magnetic field and the properties of the nanoparticles on the diffusion of drug molecules and thrombolysis efficiency.

Materials and methods

Material used. In order to synthesis and functionalize ferrite nanoparticles, FeCl₂, FeCl₃, Tetraethyl orthosilicate (TEOS), triethoxysilane (APTES), ammonia, and glutaraldehyde were purchased from Merck. The streptokinase was acquired from CSL Behring GmbH Co, Germany. Sterile water and normal saline serum as diluent were prepared from the Iranian Parenteral and Pharmaceutical Company (Tehran, Iran).

Synthesis of magnetic nanoparticles. The magnetic nanoparticles were synthesized using 16.25 g FeCl₂·4H₂O and 6.35 g of FeCl₃·4H₂O. Then, 200 mL of deoxygenated distilled water and stirring for 60 min. Then Ammonium hydroxide added dropwise to the solution to adjust the pH to 9 under inert nitrogen gas and vigorous stirrer (1000 rpm) for 5 h at 70 °C. After the system was cooled to room temperature, the black powder of magnetic nanoparticles is collected by a neodymium magnet and washed three times with distilled water and ethanol. Finally, magnetic nanoparticles dried in an oven at 60 °C.

Synthesis of ferrite-silica core–shell nanoparticles (Fe₃O₄@SiO₂). The low-temperature micro-emulsion techniques was applied to create a silica shell around the ferrite core. Fe₃O₄ (45 mg) was initially dispersed in 80 mL ethanol and 16 mL deionized water by sonication process, following by adding 0.8 mL TEOS to the suspension and sonicated well. Then, 25% NH₄OH solution was added slowly to catalyze the condensation of TEOS via increasing the pH value to 10 under magnetic stirring for 24 h. Then, the core–shell nanoparticles (Fe₃O₄@SiO₂) were consequently collected by a magnetic bar and washed well with deionized water and ethanol to remove impurities, following by lyophilizing in an oven at 60 °C.

Streptokinase loading in Fe₃O₄@SiO₂ nanoparticles. The Fe₃O₄@SiO₂ was consequently modified with APTES to introduce surface amine groups by dispersing 200 mg of Fe₃O₄@SiO₂ in 20 mL ethanol and 10 mL DDI water for 30 min. sonication, following by adding 0.63 mL APTES to solution. Then Fe₃O₄@SiO₂-APTES was rinsed with deionized water three times and separated by a magnet. For loading drug agent (streptokinase), at first, Fe₃O₄@SiO₂-APTES nanoparticles were treated with 1 mL of glutaraldehyde reagent (50% v/v) for 24 h. Then, the solution was washed with deionized water to remove unreacted agent. Consequently, 10 mg of streptokinase and 10 mL normal saline was added into the glutaraldehyde treated Fe₃O₄@SiO₂ nanoparticles. The mixture was gently shaken at room temperature for 4 h. Thereafter, the SK immobilized Fe₃O₄@SiO₂ nanoparticles was isolated by applying external magnetic field and was washed with the saline serum repeatedly.

Characterization of nanoparticles. The particle size and its distribution as well as the morphology of nanoparticles were evaluated by transmission electron microscopy (TEM) (JEM-2000 EX II; JEOL, Tokyo, Japan). For providing information regarding the presence of functional groups in the Fe₃O₄@SiO₂ nanoparticles, Fourier transform infrared spectrophotometer (FTIR-8400S, Shimadzu Company) is employed. Magnetization properties are measured by vibrating Sample Magnetometer (VSM 7400 Lake Shore) and single crystal X-ray diffraction (The D8 ADVANCE X-ray Spectrometer, a Copper X-ray tube operated at 40 kV and 40 mA, manufactured by Broker Co.) technique for identify the crystalline phases.

TEM images of nanoparticles are presented in Fig. 1. Results showed that the Fe₃O₄ nanoparticles were completely spherical and had an average size of 10 nm (Fig. 1A). After formation of SiO₂ shell (Fe₃O₄@SiO₂ nanoparticles), while the uniformity of nanoparticles was not significantly changed, the average size of nanoparticles enhanced to 30 nm (Fig. 1B). TEM images of both nanoparticles (Fig. 1A,B) also confirmed the formation of spherical nanoparticles. All diffraction peaks of the XRD patterns of the prepared nanoparticles at (220), (311), (400), (422), (511) and (440), can be easily indexed to the face-centered cubic spinel structure of Fe₃O₄ nanoparticles which matches incredibly well with the JCPDS card number 19-0629 as shown in Fig. 2A.

Magnetization curves of Fe₃O₄ and Fe₃O₄@SiO₂ are depicted in Fig. 2B. The differences in saturation magnetization (MS) between curves (Fig. 2B (I) and (II)) indicated that the silica shell formed reduced the magnetic properties of nanoparticles. The FT-IR spectra of functionalized nanoparticles are presented in Fig. 3. In Fe₃O₄ nanoparticles, the peak at 572 cm⁻¹ represents the Fe–O–Fe vibration related to the magnetite phase. Meanwhile, an absorption band at 1632 cm⁻¹ corresponding to the N–H bond vibrations indicates that the N–H band is formed during the chemical coprecipitation of Fe₂⁺ and Fe³⁺ salts induced by the addition of NH₃·H₂O base. The peak at 3433 cm⁻¹ (bending mode of H₂O) showed the existence of water molecules on the surface of Fe₃O₄ nanoparticles.
Figure 1. The TEM images of (A) Fe₃O₄, (B) Fe₃O₄@SiO₂.

Figure 2. (A) The XRD graph. (B) The VSM graphs of I: Fe₃O₄ and II: Fe₃O₄@SiO₂.
formation of the silica shell. The peak at 1551 cm\(^{-1}\) is related to the –NH\(_2\) bands in amine-derived in 
Fe\(_3\)O\(_4\)@SiO\(_2\) + APTES. The presence of a peak in Fe\(_3\)O\(_4\)@streptokinase conjugates at 3416 cm\(^{-1}\) and 2000 cm\(^{-1}\) are relevant 
to the hydroxyl group (OH), carbonyl group (C=O) respectively. And 691 cm\(^{-1}\) is related to double bond group 
(C=C). The very weak band observed at 1640 cm\(^{-1}\) was related to stretching vibration of C=C, presence of SK 
on the surface of the Fe\(_3\)O\(_4\) nanoparticles.

**Drug delivery evolution.** To assess drug release from magnetic nanoparticles, a UV–Vis spectrophotometer 
at the wavelength of 206 nm is used. To avoid particle interferences\(^{20}\), the Membrane diffusion method (reverse 
dialysis bag technique) for the assessment of in vitro drug release from magnetic nanoparticles is employed. The magnetic nanoparticles are placed inside the dialysis sacs with a molecular weight cutoff (MWCO) of 10 kDa, 
then placed into medium reservoir containers (normal saline) with some agitation. For setting the curves of the 
spectrophotometer, the optical density (OD) of peak absorption of the streptokinase at 206 nm is considered. 
Free streptokinase with standard dilutions (1 mg/mL) are prepared. In static condition, which simulates the 
complete obstruction of a vessel by a clot, 1 mL blood and 0.2 mL CaCl\(_2\) is poured in a transparent tube with 
diameter of 10 mm, after forming the clot, 9 mL saline serum add above the clot, moreover 62 µL of free strep-
tokinase or 100 µL Fe\(_3\)O\(_4\)@SiO\(_2\) are added to the tube. The results of spectrophotometry tests show that 59% of 
streptokinase are loaded on the magnetic nanoparticles. The percentage of SK loaded on the nanoparticles is 
shown in Fig. 4. Approximately 60% of the drug is placed on the nanoparticles and the drug is released in about 
4 h. At the experimenting time, all clots with their thrombolytic agent are incubated at 37 °C.

**Blood clot preparation.** Blood was obtained from students between the ages of 25 and 30 (informed con-
tent obtained from all students. Meanwhile Helsinki guidelines followed for the study and students who vol-
untarily participate in human subject research after giving informed consent to be the subject of the research). 
Informed consents were provided by the volunteers. The clots were produced by reaction of 1 mL blood with 
200 µL CaCl\(_2\). Percentage of clot dissolution has been used as a measure of dissolved clot (reduction in clot 
weight) (CW %).

**Micro CT-scan.** A desktop micro-Computed Tomography (micro-CT) scanner was used in this study 
(LOTUS-NDT, Behin Negareh Co., Tehran, Iran). LOTUS-NDT has a cone beam micro-focus X-ray source and a 
flat panel detector. The X-ray tube voltage and its current were set to 50 kV and 90 µA, respectively. No added 
filtration was used in this study. The total scan time was ~3 h and the nominal resolution was ~11 microns. All 
the protocols settings process was controlled by LOTUS NDT-ACQ software. The acquired 3D data was recon-
structed using LOTUS NDT-REC by a standard Feldkamp, Davis, Kress (FDK) algorithm.
Experimental setting. To study the effect of static magnetic field intensity on thrombolysis, the experiments are designed in 8 groups and 4 levels of magnetic field strength [0.1, 0.2, 0.3 (permanent neodymium magnet) and 0.5 T (electromagnet)] are examined as shown in Fig. 5. The permanent magnet is a rectangular cube (3×2×1 cm) and the intensity of the magnetic field is measured at the surface of the magnet. It should be noted that the magnet is in contact with the test tube containing the clot and the distance from the surface of the magnet to the upper surface of the clot is 10 mm. The tests are performed on a test tube that has no fluid flow and is similar to a complete blockage of a vessel by a clot. The experiments were repeated three times. Statistical significance was measured by one-way analysis of variance followed by Dunnett's multiple comparison tests. Significance was ascribed at p < 0.05.

Ethical approval. All methods were carried out in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Nursing Committee for Biological Ethics and Biomedical Research at the Islamic Azad University of Shirvan on November 7, 2019, No.

Figure 4. The efficiency of drug loaded on magnetic nanoparticles [error bars indicate standard deviation p < 0.05].

Figure 5. Experimental setting.
The author gives his consent for publishing all subjects of the paper. All participants give their consent for publishing all subjects of the paper.

**Results**

Figure 6 shows the efficacy of thrombolysis in different conditions. As can be seen from Fig. 6, there is no difference between the control group and nanoparticles. However, administration of nanoparticles carrying thrombolytic agent rises thrombolysis efficiency to 42%. Figure 6 shows that the employing a magnetic field increases the thrombolysis efficiency compared with administration of the free drug or even magnetic nanoparticles carrying SK. Increasing the intensity of the magnetic field from 0.1 to 0.3 T leads to a surge in clot dissolution rate from 55 to 89%, respectively. Additionally, micro-CT scan images have been employed to study the motion of magnetic nanoparticles carrying drugs under a magnetic field.

While the schematic of the effect of gravity force and magnetic force on magnetic nanoparticles are illustrate on Figs. 7A, B, 8, 9, 10, 11, 12 confirm that magnetic nanoparticles penetrate into the clot under a magnetic field. Obviously, by increasing magnetic field intensity from 0.1 to 0.3 T, the amount of penetration and the number of magnetic nanoparticles increase. Figure 8 shows that in the absence of a magnetic field, the magnetic nanoparticles are located on the surface of the blood clot and have not penetrated the clot. In Fig. 9, the magnetic field strength is 0.1 T, the magnetic nanoparticles have penetrated the clot, as shown in the side view. As the magnetic field strength increases to 0.2 T, Fig. 10, the penetration of magnetic nanoparticles into the clot increases compared with that of applying 0.1 T. Figure 11 also shows that as the magnetic field strength increased to 0.3 T, the penetration of magnetic nanoparticles into the clot increased compared to the magnetic field strength of 0.1 and 0.2 T respectively. Figure 12 also displays the penetration of magnetic nanoparticles under a 0.5 T magnetic field created by an electromagnet. And the employing a 0.5 T magnetic field causes magnetic nanoparticles to move inside the clot, creating a funnel-shaped path (like a tornado) inside the clot.

**Discussion**

Magnet therapy and the effect of static magnetic field intensity on the treatment of diseases are very controversial. It has been reported that thrombolysis with magnetic nanoparticles carrying thrombolytic agents is more effective than administering the free drugs at the same dose. The phenomenon of diffusion and mass transport process is effective in dissolving the clot with the thrombolytic drug. It is reported that one of the best strategies to enhance the thrombolysis without increasing the tPA concentration is improving the mass transport process during thrombolysis. Agitating the plasma or blood flow is one of mechanism to achieve this aim. Researchers confirmed that creating a drop pressure on clot or rising blood flow resulting in heightening the permeation of plasmin activators to the thrombus. A computer simulation of clot lysis process based on the reaction–diffusion–convection equations show that raising the pressure drop from 1 to 10 and 20 Pa heighten the lysis strongly. A higher pressure drops increase the penetration of tPA in the thrombus. When the clot is dense or the drop pressure is low, the clot lysis is controlled by diffusive process instead of permeation.
solutions such as increased pressure are virtually impossible and can pose many risks. It is confirmed that in the absence of any permeations, the dominant mechanism is limited to diffusion equations. The effectiveness of thrombolytic therapy is determined by accessibility of thrombus compartments to plasminogen activators and, therefore, depends on permeability of thrombolytic molecules to clot macromolecules. Therefore, enhancing mass transfer or accumulation of plasminogen activators during thrombolytic therapy play a significant role in thrombolytic efficiency.

As, it is confirmed that there is a direct relationship between the clot thrombolysis and the penetration of thrombolytic agent in the thrombus, one of the best strategies to promote the thrombolysis efficacy, without increasing the drug concentration (or low SK concentration), is improving the diffusion during thrombolysis. The results (Fig. 6) confirm that there is a direct relationship between clot thrombolysis and magnetic field strengths. This may be due to the effect of the static magnetic field strengths on the magnetic nanoparticles carrying thrombolytic agents or other parameters, which is further studied below.

The two phenomena of mass transport process and diffusion can be effective in increasing the efficiency of the thrombolytic drugs. Because the drug is placed on magnetic nanoparticles, the motion of the nanoparticles and the forces acting on the nanoparticles affect the mass transfer of the drug. In addition, the diffusion phenomenon that follows Fick’s law also affects the movement of drug molecules. When drug-carrying nanoparticles

---

Figure 7. The schematic of the effect of different forces on magnetic nanoparticle (A) gravity force, (B) magnetic force.

Figure 8. Micro CT-scan image clot without magnetic field. (A) Schematic of applying magnetic field on clot and magnetic nanoparticles. (B) Side view. (C) Top view.
are exposed to a magnetic field in a fluid, they are affected by several forces, including magnetic force ($F_m$), gravity ($F_g$), viscous force ($F_d$) and buoyancy ($F_b$). While the force of gravity and magnetic force try to push the nanoparticles down, the buoyancy force ($F_b$) pushes up as shown Fig. 7.

$$F = F_g + F_b + F_m - F_d,$$

where $F_g$ and $F_b$ are gravity and buoyancy, respectively and $F_d$ and $F_m$ is viscous force (drag) and magnetic force, respectively.

Figure 9. Micro CT-scan image clot under magnetic field 0.1 T. Schematic of applying magnetic field on clot and magnetic nanoparticles, side view and top view.

Figure 10. Micro CT-scan image clot under magnetic field 0.2 T. Schematic of applying magnetic field on clot and magnetic nanoparticles, side view and top view.
The magnetic force is given by:

\[ F_{\text{magnet}} = \frac{\mu_0}{3} (4\pi R^3) (M_p \nabla B_z), \]  

where \( \mu_0 = 4\pi \times 10^{-7} \) is the magnetic permeability of the vacuum, \( M_p \) is the magnetization of \( \text{Fe}_3\text{O}_4 \) in a given magnetic field \( B \).

In addition, the drag force of viscosity on a small sphere moving through a viscous fluid is given by:

\[ F_d = 6\pi u R v, \]  

**Figure 11.** Micro CT-scan image clot under magnetic field 0.3 T. Schematic of applying magnetic field on clot and magnetic nanoparticles, side view and top view.

**Figure 12.** Micro T-scan image clot under magnetic field 0.5 T. Schematic of applying magnetic field on clot and magnetic nanoparticles, side view and top view.
where $F_d$ is the frictional force—known as Stokes’ drag—acting on the interface between the normal saline and the particles; $\mu$ is the dynamic viscosity; $R$ is the radius of the spherical nanoparticle; $v$ is the flow velocity relative to the nanoparticle.

The buoyancy force is given by:

$$F_b = \rho g \frac{4}{3} \pi R^3.$$  

(4)

And the gravity force is given by:

$$F_g = \rho g \frac{4}{3} \pi R^3.$$  

(5)

The excess force $F_x$ due to the difference between the weight and buoyancy of the sphere (both caused by gravity) is given by:

$$F_x = (\rho_p - \rho_f) g \frac{4}{3} \pi R^3.$$  

(6)

With $\rho_p$ and $\rho_f$ the mass densities of the nanoparticle and fluid (normal saline), respectively, and $g$ the gravitational acceleration.

Although the phenomenon of diffusion occurs in all cases (from free drug to drug delivery by magnetic nanoparticles), but in the case of free drug, streptokinase, the diffusion phenomenon dominates during the process. In case of drug delivery by nanoparticles, in the absence of magnetic force, gravity plays a major role in transporting the nanoparticles coated with drug molecules to the clot surface. When magnetic nanoparticles are under a magnetic field, the magnetic force governs the motion of particles (the magnetic force will be much larger than the gravity force).

**Thrombolysis efficacy of free SK.** Figure 6 shows that the thrombolysis efficacy of free SK is around 37%. In the case of the free drug—streptokinase—the penetration phenomenon is predominant. Based on first Fick’s law, SK molecules under random thermal motion tend to spread from a region of higher concentration (normal saline) to a region of lower concentration (clot) as follows:

$$F = -D \frac{\partial C}{\partial X}.$$  

(7)

where $C$ is the concentration of the diffusing particles ($C_2 - C_1$) is the difference in concentration for the direction of flow (from $C_1$ to $C_2$), $F$ is the diffusion flux (particles per square meter per second), $X$ is the position (the dimension of which is length), and $D$ is the diffusion constant, which has units of cm$^2$ per second.

According to first Fick’s law, the efficiency of clot lysis can be related to the concentration of the drug. Drug molecules (SK) breakdown the fibrin, the major constituents of blood thrombi, thereby dissolving clots. However, the mesh of cross-linked fibrin protein (the aggregated platelets and red blood cells) forming a biological barrier (especially on the surface of the clot) inhibiting the passage of drug molecules to the inner of the clot. In principle, the lysis of the clot by thrombolytic agents is a combination process of diffusion and chemical reaction. Two steps involved in thrombolysis processes: firstly, is the diffusing of streptokinase molecules to the thrombus surface, secondly is activating plasminogen and converting into enzyme plasmin, which degrading the fibrin into a fibrin-hydrolyzed product.

Fick’s diffusion law, which states that the diffusion flux is proportional to the concentration gradient, employing a high concentration of thrombolytic agent leads to enhancing the rate of clot lysis. SK molecules tend to follow a concentration gradient (from solvent to clot), this diffusion process leads to clot-dissolving. It has been reported that there is a direct relationship between the dosage of SK and thrombolysis. Administration of higher concentrations of streptokinase leads to increasing clot dissolution. Consequently, as the concentration of SK (in contact with the clot surface), or diffusion constant being increased, the dissolving of the clot will be enhanced. So, attachment the drug molecules on the surface of the nanoparticles which are in contact with the clot surface will increase the concentration of the drug on the surface, meanwhile applying magnetic force enhances the diffusion constant and accelerate the thrombolysis process as mention below.

**Thrombolysis efficacy of MNP@SiO$_2$ (without magnet).** As shown in Fig. 7, the efficacy of Fe$_3$O$_4$@SiO$_2$-SK + is around 20% more than administration-free SK, at the same drug dosage (62 mg/mL). In this case, the phenomenon of diffusion and the phenomenon of the mass transport process are done with the help of magnetic nanoparticles. In the absence of magnetic force, the force of gravity is the dominant force that tends to place nanoparticles on the surface of the clot, leading to an increase in the concentration of streptokinase in the clot surface over a shorter period of time. Therefore, improving the thrombolysis could be related to the increasing local SK concentrations on the surface of the clot due to gravity, which provides more effect on the diffusion of drug molecules and clot-dissolving. While in free SK, molecules of streptokinase are dissolved in normal saline above the clot which leads to the low concentration of drug molecules in the clot contact with clot surface and being less effective, in the case of MNP@SiO$_2$ + SK, magnetic nanoparticles (Fe$_3$O$_4$) fall on the surface of clot, due to gravity, and the more streptokinase molecules are in contact with the surface of the clot, therefore, the drug concentration will be higher at the surface of the clot ($C_{(MNP@SiO_2)} > C_{(Free SK)}$). The schematic of the effect of gravity on nanoparticles is shown in Fig. 7A. Micro-CT scan image (Fig. 8) shows that magnetic
Thrombolysis efficacy of MNP@SiO₂ + drug + magnet. In the case of MNP@SiO₂ + drug + magnet, there is a growth in thrombolysis efficiency compared to free SK and even non-magnetic magnetic nanoparticles as shown in Fig. 6. According to Eq. (2), this effect can be attributed to the effect of magnetic force. The schematic of gravity and magnetic force on nanoparticles is shown in Fig. 7B. The magnetic force, which is much larger than the force of gravity, causes the nanoparticles to move from the injection site to the surface of the clot. This causes the drug-carrying nanoparticles to be located on the surface of the clot and the drug concentration to increase on the clot surface, which leads to an increase in thrombolysis efficiency. In addition, the penetration of nanoparticles into the clot can be an explanation for increasing the efficiency of the clot by increasing the magnetic field, which is confirmed by micro-CT-scan images. Micro-CT-scan images (Figs. 8, 9, 10, and 11) also show that as the magnetic field increases, nanoparticles penetrate into the clot, and the rate of penetration into the clot rises with increasing magnetic field strength. These images also display that as the magnetic field intensifies, not only does the penetration depth of the nanoparticles increase, but also the number of nanoparticles penetrating into the clot.

The penetration of the drug into the clot allows the drugs to break down the fibrins inside the clot, which is not possible with the free drug. As the magnetic field intensifies, more fibrin inside the clot is exposed to the drug and broken down. Whereas a free drug or the drug is carrying by nanoparticles (without a magnetic field) is used, the drug molecules are only in contact with the fibrins on the surface and not with the fibrins on the surface of the clot, but when a magnetic field is used, the molecules of the drug can penetrate into the depth of clot and break the fibrins inside the clot. In fact, the magnetic force guides the thrombolytic agent into the clot by magnetic nanoparticles (like injecting a drug into a tissue with a needle).

In addition to the penetration of nanoparticles into the clot, the time of contact nanoparticles with the clot is also significant.

The magnetic field applies a force on magnetic nanoparticles that accelerate the movement of the nanoparticles towards the clot surface and the nanoparticles carrying a thrombolytic agent reach the surface of the clot in a shorter time, and the drug will be in contact with the clot longer. According to physic laws, the time of falling (moving from the injecting site of nanoparticles to the surface of clot) is given by:

$$t = \frac{2Lm}{F_{\text{total}}}.$$  

L is the distance between injecting site and the surface of clot and m is the mass of nanoparticles.

Therefore, the nanoparticles carry the drug, increasing the contact time of the nanoparticles with the clot causes the drug molecules to be in contact with the fibrins longer and there is more time for a chemical reaction, which increases fibrin breakdown.

Meanwhile, nanoparticles fall to the surface of the clot in less time and, as a result, stay in contact with the clot surface for a longer time. Rapid placement of nanoparticles carrying thrombolytic agent on the surface of the clot leads to increasing the contacting time of nanoparticles with clot surface. Based on Fick’s second law reveals that, in diffusive processes, there is a fundamental relation between the contacted time and the square of the length over which diffusion takes place as below:

$$\frac{\partial \varphi}{\partial t} = -D\frac{\partial^2 \varphi}{\partial X^2}.$$

$\varphi$ is the concentration in dimensions.

Increasing the time of contacting drug molecules with clot surface leading to increasing the length of diffusion in the clot. As a result, the thrombolysis efficiency when streptokinase loaded on a nanoparticle is greater than is free SK (a greater number of SK molecules are in contact with clot surface compare with that of free SK that led to increasing thrombolysis efficacy).

According to Nernst–Planck equation, the magnetic field also affects the diffusion. In the static electromagnetic conditions, one obtains the steady-state Nernst–Planck equation:

$$J = -D \nabla c + \mu c + \frac{D_e c}{k_bT} \left( \nabla \varphi + \frac{\partial M}{\partial t} \right),$$

where $J$ is the diffusion flux density, $t$ is time, $D$ is the diffusivity of the chemical species, $c$ is the concentration of the species, $z$ is the valence of ionic species, $k_b$ is the Boltzmann constant, $T$ is the temperature, $\mu c$ is velocity of fluid, $M$ is the magnetic vector potential.

Besides, magnetic force enhances the diffusion constant based on the Nernst–Planck equation, which states that the addition of a magnetic field will increase the penetration phenomenon. Therefore, the increasing magnetic field not only makes the nanoparticles get more in contact with the clot surface faster (SK concentration increases faster) but also rises the diffusion constant which leads to increasing the thrombolysis efficacy as shown in Fig. 6.

The magnetic field causes the nanoparticles to not only penetrate the surface of the clot but also penetrate inside the clot. Because these nanoparticles carry drugs, the magnetic field increases the concentration of the drug and increases the contact of the drug molecules with the clotted fibrins. Other researchers have reported similar phenomena in other areas, such as the penetration of magnetic nanoparticles under a magnetic field into the clot.
cancer cell. The penetration of magnetic nanoparticles under the magnetic field in the clot mesh increases the effect of thrombolytic drug. The clot, as shown in Fig. 13, has a mesh-like structure composed of fibrin, red blood cells and platelets. The drug-carrying nanoparticles can pass through these meshes due to magnetic force. In all micro-CT scan images, nanoparticles have penetrated in the middle of the clot, and this can be clearly seen in Fig. 12. As shown in Fig. 12, nanoparticles in a strong magnetic field (0.5 T) are funnel-shaped, which could be due to the shape of the magnetic field of the magnetic coil, which is stronger in the middle and weaker around it. However, by changing the position of the magnetic field or by rotating it, an equal distribution of nanoparticles can be created in the clot.

Conclusion

This study showed that increasing the intensity of the magnetic field leads to increasing the efficiency of thrombolysis by magnetic nanoparticles carrying a thrombolytic agent. The magnetic field causes the magnetic nanoparticles not only to locates on the surface of the clot but also to penetrate into depth of the clot. Practicing the magnetic field can also improve the transport of magnetic nanoparticles carrying thrombolytic agents, which can ultimately increase drug concentration at the surface and depth of clot in a short time, leading to increasing thrombolysis efficiency.

In the future, the effect of nanoparticle size and rotating of static magnetic field on thrombolysis will be studied. An attempt will be made to study the effect of static magnetic field intensity on the rate of penetration into cells especially cancer one. Determining the relationship between the intensity of the magnetic field and the depth of penetration of magnetic nanoparticles into cancer cells will be researched.

Received: 27 March 2021; Accepted: 6 August 2021

Published online: 10 September 2021

References

1. Li, Q. et al. Moderate intensity static magnetic fields prevent thrombus formation in rats and mice. Bioelectromagnetics 41(1), 52–62 (2020).
2. Colbert, A. P., Souder, J. & Markov, M. Static magnetic field therapy: Methodological challenges to conducting clinical trials. Environmentalist 29(2), 177–185 (2009).
3. Khalil, I. S. et al. Magnetic localization and control of helical robots for clearing superficial blood clots. APL Bioeng. 3(2), 026104 (2019).
4. Colbert, A. P. et al. Static magnetic field therapy: A critical review of treatment parameters. Evid. Based Complement. Altern. Med. 6(2), 133–139 (2009).
5. Kleven, R. T. et al. Accelerated sonothrombolysis with Definity in a xenographic porcine cerebral thromboembolism model. Sci. Rep. 11(1), 1–11 (2021).
6. Greits, I. et al. Non-exponential magnetic relaxation in magnetic nanoparticles for hyperthermia. J. Magn. Magn. Mater. 526, 167682 (2021).
7. Gawali, S. L. et al. Immobilization of protein on Fe₃O₄ nanoparticles for magnetic hyperthermia application. Int. J. Biol. Macromol. 166, 851–860 (2021).
8. Suzuki, K. et al. Effect of mechanical thrombectomy without vs with intravenous thrombolytic on functional outcome among patients with acute ischemic stroke: The SKIP Randomized Clinical Trial. JAMA 325(3), 244–253 (2021).
9. Paul, C. L. et al. How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke care. Implement. Sci. 11(1), 1 (2016).
10. Dirks, M. et al. Promoting acute thrombolysis for ischaemic stroke (PRACTISE). Int. J. Stroke 2(2), 151–159 (2007).
11. Bandmann, N. & Nygren, P. –Å. Combinatorial expression vector engineering for tuning of recombinant protein production in Escherichia coli. Nucleic Acids Res. 35(3), e32 (2007).
12. Wang, M. et al. Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles. *J. Biomed. Nanotechnol.* 8(4), 624–632 (2012).
13. Hu, J. et al. Magnetically active Fe₃O₄ nanorods loaded with tissue plasminogen activator for enhanced thrombolysis. *Nano Res.* 9(9), 2652–2661 (2016).
14. Tadayon, A., Jamshidi, R. & Esmaeili, A. Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases. *Int. J. Pharm.* 495(1), 428–438 (2015).
15. Chen, J.-P. et al. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle. *Int. J. Nanomed.* 7, 5137 (2012).
16. Jin, H.-J. et al. Urokinase–coated chitosan nanoparticles for thrombolytic therapy: Preparation and pharmacodynamics in vivo. *J. Thromb. Thrombolysis* 36(4), 458–468 (2013).
17. Torno, M. D. et al. Improvement of in vitro thrombolysis employing magnetically-guided microspheres. *Thromb. Res.* 121(6), 799–811 (2008).
18. Wardani, R. K. et al. Synthesis and characterization of nanoparticle magnetite for biomedical application. In *AIP Conference Proceedings*. (AIP Publishing LLC, 2019).
19. Arablou, J. et al. Health technology assessment of magnet therapy for relieving pain. *Med. J. Islam Repub. Iran.* 14(1), 5–12 (2017).
20. Cheng, R. et al. Acceleration of tissue plasminogen activator-mediated thrombolysis by magnetically powered nanomotors. *ACS Nano* 8(8), 7746–7754 (2014).
21. Bajd, F. & Šeša, I. Mathematical modeling of blood clot fragmentation during flow-mediated thrombolysis. *Biophys. J.* 104(5), 1181–1190 (2013).
22. Wu, J.-H., Siddiqui, K. & Diamond, S. L. Transport phenomena and clot dissolving therapy: An experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis. *Thromb. Haemost.* 72(1), 105–12 (1994).
23. Herrera, S. & Comerota, A. J. Embolization during treatment of deep venous thrombosis: Incidence, importance, and prevention. *Tech. Vasc. Interv. Radiol.* 14(2), 58–64 (2011).
24. Kumbasar, S. D. et al. Effect of intraaortic balloon counter-pulsation on QT dispersion in acute anterior myocardial infarction. *Int. J. Cardiol.* 65(2), 169–172 (1998).
25. Miyu, M. & Domogatsky, S. P. Penetration of macromolecules into contracting blood clot. *Biophys. J.* 63(3), 862–863 (1992).
26. Bakhteeva, I. et al. Magnetic field-enhanced sedimentation of nanoparticle magnetite in water flow. *Environ. Technol.* 36(14), 1828–1836 (2015).
27. Conlisk, A. T. Essentials of Micro- and Nanofluidics: With Applications to Biological and Chemical Sciences (Cambridge University Press, 2012).
28. Lac, E. et al. Spherical capsules in three-dimensional unbounded Stokes flow: Effect of the membrane constitutive law and onset of buckling. *J. Fluid Mech.* 516, 303–334 (2004).
29. Kirby, B. J. Micro- and Nanoscale Fluid Mechanics: Transport in Microfluidic Devices (Cambridge University Press, 2010).
30. Alexiou, C. et al. Targeting cancer cells: Magnetic nanoparticles as drug carriers. *Eur. Biophys. J.* 35(5), 446–450 (2006).

**Author contributions**

A.M. conceived the original idea and carried out the experiment. J.V. contributed to the final version of the manuscript. F.A. supervised the project. A.F. developed original idea and the theory. All authors discussed the results and contributed to the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to A.M.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

© The Author(s) 2021